REG - ReNeuron Group plc - Notification of Preliminary Results

ReNeuronAnnouncement

04/07/2018 14:15

RNS Number : 6173T
ReNeuron Group plc
04 July 2018
 


 
 
 
 



4 July 2018


AIM: RENE



ReNeuron Group plc
("ReNeuron" or the "Company")
 
Notification of Preliminary Results
 
ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, will announce its preliminary results for the year ended 31 March 2018 on Thursday 12 July 2018.
 
A meeting for analysts will be held at 10.00am on the morning of the results at the offices of Buchanan, 107 Cheapside, London EC2V 6DN.
 
To access a webcast of the analyst presentation, please log on to the following web address approximately 10 minutes before 10.00am on the day of the results:
 
http://webcasting.buchanan.uk.com/broadcast/5afc4a0b1fcda841bf20f48d 
 
A recording of the presentation will be made available on ReNeuron's website, www.reneuron.com.
 
ENDS
 
ENQUIRIES:
 
 



ReNeuron


+44 (0)20 3819 8400




Olav Hellebø , Chief Executive Officer








Michael Hunt, Chief Financial Officer








Buchanan


+44 (0) 20 7466 5000




Mark Court, Sophie Wills, Tilly Abraham


















Stifel Nicolaus Europe Limited


+44 (0) 20 7710 7600




Jonathan Senior, Stewart Wallace, Ben Maddison (NOMAD and Broker)








N+1 Singer Advisory LLP


+44 (0) 20 7496 3000




Mark Taylor (Joint Broker)







 
About ReNeuron
 
ReNeuron is a leading, clinical-stage cell therapy development company.  Based in the UK, its primary objective is the development of novel cell-based therapies targeting areas of significant unmet or poorly met medical need.  
 
ReNeuron has used its unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered "off-the-shelf" to any eligible patient without the need for additional immunosuppressive drug treatments.  The Company has therapeutic candidates in clinical development for disability as a result of stroke and for the blindness-causing disease, retinitis pigmentosa.   
 
ReNeuron is also advancing its proprietary exosome technology platform as a potential new nanomedicine targeting cancer and as a potential delivery system for drugs that would otherwise lack adequate capacity to penetrate to their site of action.
 
ReNeuron's shares are traded on the London AIM market under the symbol RENE.L.  Further information on ReNeuron and its products can be found at www.reneuron.com.
 
 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NORLLFLVDIISIIT